Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Rossella Elisei
University of Pisa
273Publications
59H-index
14.6kCitations
Publications 273
Newest
Published on Sep 1, 2019in European Journal of Cancer 6.68
Laura D. Locati23
Estimated H-index: 23
,
A. Piovesan + 19 AuthorsGuido Fedele
Abstract Background Lenvatinib is a multi-kinase inhibitor approved for patients with radioactive iodine (RAI)–resistant differentiated thyroid cancer (DTC). Before the drug approval from the Italian National Regulatory Agency, a compassionate use programme has been run in Italy. This retrospective study aimed to analyse data from the first series of patients treated with lenvatinib in Italy. Methods The primary aim was to assess the response rate (RR) and progression-free survival (PFS). Second...
Published on Jul 5, 2019in Endocrine 3.30
Teresa Ramone (UniPi: University of Pisa), Cristina Romei36
Estimated H-index: 36
(UniPi: University of Pisa)
+ 5 AuthorsRossella Elisei59
Estimated H-index: 59
(UniPi: University of Pisa)
Pourposes We investigated the expression of RET9 and RET51 isoforms in medullary (MTC), papillary (PTC) thyroid carcinoma, normal thyroid tissues, and pheochromocytoma (PHEO) to verify if these isoforms are present also in follicular thyroid cell-derived tissues, and if there is a differential expression of RET9 and RET51 in MTC.
Published on Jul 1, 2019in The Journal of Clinical Endocrinology and Metabolism 5.61
Rossella Elisei59
Estimated H-index: 59
(UniPi: University of Pisa),
Antonio Matrone7
Estimated H-index: 7
(UniPi: University of Pisa)
+ 12 AuthorsFrancesco Latrofa20
Estimated H-index: 20
(UniPi: University of Pisa)
Published on Apr 1, 2019in Annales D Endocrinologie 1.43
Rossella Elisei59
Estimated H-index: 59
,
Valeria Bottici15
Estimated H-index: 15
+ 4 AuthorsCristina Romei36
Estimated H-index: 36
Abstract Medullary thyroid cancer (MTC) is a rare thyroid tumor whose prevalence is 3–5% among all thyroid tumors. The pathogenesis of MTC is mainly related to germline or somatic RET activating point mutations that are causative of hereditary and sporadic cases, respectively. Hereditary MTC can occur as multiple endocrine neoplasia type 2A (MEN 2A), type 2B (MEN 2B) and familial MTC (FMTC) that differ for the association with other endocrine neoplasia. Germline RET point mutations are prevalent...
Published on Mar 5, 2019in Oncotarget
Anello Marcello Poma2
Estimated H-index: 2
,
Vincenzo Condello1
Estimated H-index: 1
+ 4 AuthorsFulvio Basolo62
Estimated H-index: 62
Published on Mar 1, 2019in The Lancet Diabetes & Endocrinology 24.54
Frederic Castinetti24
Estimated H-index: 24
(French Institute of Health and Medical Research),
Steven G Waguespack37
Estimated H-index: 37
(University of Texas MD Anderson Cancer Center)
+ 63 AuthorsXiao Ping Qi1
Estimated H-index: 1
(Anhui Medical University)
Summary Background Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. Methods This study was a retrospective,...
Published on Mar 1, 2019in Endocrinology and Metabolism Clinics of North America 3.31
David Viola16
Estimated H-index: 16
,
Rossella Elisei59
Estimated H-index: 59
Medullary thyroid cancer (MTC) is rare but aggressive. It can be cured only if intrathyroid at diagnosis. MTC can be sporadic (75%) or familial (25%) and the 2 forms are distinguished by RET mutations analysis. Calcitonin is the specific serum marker; its doubling time is the most important prognostic factor for survival and progression; 30% of MTC patients have distant metastases at diagnosis and, when progressing, systemic therapy with vandetanib or cabozantinib should be considered. Before st...
Published on Feb 1, 2019in Endocrine-related Cancer 4.77
Mimi I-Nan Hu17
Estimated H-index: 17
,
Rossella Elisei59
Estimated H-index: 59
(UniPi: University of Pisa)
+ 8 AuthorsJolanta Krajewska10
Estimated H-index: 10
(Curie Institute)
Published on Jan 1, 2019
Rossella Elisei59
Estimated H-index: 59
,
Cristina Romei36
Estimated H-index: 36
Medullary thyroid cancer is very rare since it represents about 0.2% of all human tumors. It can be sporadic (75%) or familial (25%), and in both cases the pathogenesis is related to the presence of activating mutations of RET oncogene at somatic or germline level, respectively. Total thyroidectomy and central neck nodes dissection is the treatment of choice even when the tumor is apparently restricted to the thyroid. Lateral neck dissection should be reserved to cases with an evident involvemen...
12345678910